8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression
US-12168019-B1 · Dec 17, 2024 · US
US9301966B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9301966-B2 |
| Application number | US-201313739813-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 11, 2013 |
| Priority date | Jan 11, 2013 |
| Publication date | Apr 5, 2016 |
| Grant date | Apr 5, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to nutritional composition(s) comprising a carbohydrate source, a protein source, a fat source and magnesium threonate. Magnesium threonate may provide neurological health benefits when consumed. The disclosure further relates to methods of promoting neurological health by providing a nutritional composition comprising magnesium threonate. Additionally, the disclosure relates to methods of promoting GI tolerance in a pediatric subject by providing a nutritional composition comprising magnesium threonate.
Opening claim text (preview).
What is claimed is: 1. A nutritional composition comprising per 100 kcal: (i) between about 6 g and about 22 g of a carbohydrate source, (ii) between about 1 g and about 7 g of a protein source, (iii) between about 1 g and about 10.3 g of a fat source, and (iv) about 4.9 mg/100 kcal to about 45 mg/100 kcal of magnesium threonate. 2. The nutritional composition of claim 1 , further comprising a prebiotic. 3. The nutritional composition of claim 2 , wherein the prebiotic is selected from the group consisting of polydextrose and galacto-oligosaccharide. 4. The nutritional composition of claim 1 , further comprising DHA from about 5 mg to about 75 mg. 5. The nutritional composition of claim 1 , further comprising a probiotic from about 1×10 4 cfu to about 1.5×10 10 cfu. 6. The nutritional composition of claim 1 , wherein the nutritional composition is an infant formula. 7. A method of promoting GI tolerance in a pediatric subject by providing a nutritional composition comprising between about 6 g and about 22 g of a carbohydrate source, between about 1 g and about 7 g of a protein source, between about 1 g and about 10.3 g of a fat source, and between about 4.9 mg and about 45 mg of magnesium threonate per 100 kcal of nutritional composition to a pediatric subject, wherein the occurrence of oxidative neuronal cell death is reduced. 8. The method of claim 7 , wherein the nutritional composition comprises per 100 kcal: (i) between about 6 g and about 22 g of a carbohydrate source; (ii) between about 1 g and about 7 g of a protein source; (iii) between about 1 g and about 10.3 g of a fat source; (iv) between about 0.1 mg and about 1 mg of polydextrose; and (v) between about 0.1 mg and about 1 mg of galacto-oligosaccharide. 9. The method of claim 7 , wherein the nutritional composition comprises magnesium threonate from about 6 mg/100 kcal to about 26 mg/100 kcal. 10. The method of claim 7 , wherein the nutritional composition comprises magnesium threonate from about 15 mg/100 kcal to about 25 mg/100 kcal. 11. The method of claim 7 , wherein the nutritional composition further comprises DHA. 12. The method of claim 7 , wherein the nutritional composition is an infant formula. 13. A method of promoting neurological health in a pediatric subject by providing to a pediatric subject a nutritional composition comprising between about 6 g and about 22 g of a carbohydrate source, between about 1 g and about 7 g of a protein source, between about 1 g and about 10.3 g of a fat source, and between about 4.9 mg and about 45 mg magnesium threonate per 100 kcal, wherein the occurrence of oxidative neuronal cell death is reduced. 14. The method of claim 13 , wherein the nutritional composition comprises magnesium threonate from about 6 mg/100 kcal to about 26 mg/100 kcal. 15. The method of claim 13 , wherein the nutritional composition comprises magnesium threonate from about 15 mg/100 kcal to about 25 mg/100 kcal. 16. The method of claim 13 , wherein the nutritional composition further comprises DHA. 17. The method of claim 13 , wherein the nutritional composition is an infant formula.
having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids · CPC title
Milk; Whey; Colostrum · CPC title
having two or more hydroxy groups, e.g. gluconic acid · CPC title
Inorganic salts, minerals or trace elements · CPC title
having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.